PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Cited by
Items 501–538 of 538
Fasinu, P. S., Coric, T., & Wilborn, T. W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00458-9
Real World Evidences and Identifying the Gaps and Future Prospects with Incretin Therapy in India
Khare, J., Ghosh, M. A., Kaduskar, A., Babu, V., Mohan, B. J., AHMED, D. R., Poul, S., Singh, M. M., Gupta, R., Singh, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_26
Semaglutide for Organ Protection
Kharb, S., Bhattacharjee, B., Karuppan, A., V, Khaire, S. S., Routray, P., Ganta, S., Pakhale, K., Pareek, R., Matta, R., Sabharwal, M., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_27_26
Cardio-Kidney-Metabolic Syndrome and Role of Oral Semaglutide
Roy, N., Nallaperumal, S., Mondal, S., Mathur, R., Prakash, A. S., Chakraborty, S., Vedire, A., Ankathi, S. K., Bande, A. R., & Boppana, R. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_24_26
Ladeira, A. L. F., Maia, J. J. S., Ferreira, M. L., Oliveira, E. M. S., & Pereira, L. M. D. O. (2026) · Revista Tópicos. · doi:10.70773/revistatopicos/781810135
The systems medicine view of semaglutide: from clinical trials to molecular mechanisms
Vitorino, R. M. P. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2695172
“Additional evidence from early-stage diabetes studies (NCT02906930, NCT03018028) and cross-ethnic assessments supported persistent benefits [39].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Gandham, D. S., Pogadapula, B. S., Roopavath, S. D., & Manyam, S. S. D. (2026) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.07.0626.17a10
Im, S., Lee, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070826
“The tirzepatide dose was fixed at 14 mg, which was selected with reference to the highest marketed strength of the benchmark drug, Rybelsus [44].”
Different Clinical Questions Need Different Estimands
Keene, O. N., Lynggaard, H., Fletcher, C., Wright, D., & Terrill, P. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01012-z
Khan, S. M., Khan, M. S., Arumugam, A., Biswas, M., Saini, A. K., & Kollipara, S. (2026) · Journal of Clinical and Translational Research · doi:10.36922/jctr026250056 · Cited by 1
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Yokoyama, T., Uchino, T., Yazawa, Y., Ueno, S., & Tsuji, D. (2026) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-026-00617-8
Zhou, S., & Dong, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108369
Ciesielska, J., Bartosik, K., Niewęgłowski, M., Marczuk, S., Nazaruk, I., & Wyroślak-Najs, J. (2026) · Clinical Diabetology · doi:10.5603/cd.112355
A microencapsulation strategy for intranasal semaglutide delivery
Baldelli, A., Oğuzlu, H., Weng, Y., Singh, A., & Pratap-Singh, A. (2026) · Journal of Microencapsulation · doi:10.1080/02652048.2026.2722030
“The former, a non-invasive technique (Aroda et al. 2019) reduces the side effects of the therapy by preventing the development of thyroid gland tumours, while the latter bypasses the complexity of the digestive system (a drawback of the oral route), such as the digestive enzymes, mucus and mucosal…”
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities
Vahora, S., Shah, V., & Patel, B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04185-2 · Cited by 2
“%) similar to that observed with the 1.0 mg subcutaneous semaglutide injection, despite the oral’s 100-fold lower bioavailability [7, 9].”
InfluentialDoosti, M., & Qaoud, M. T. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108941
Tansey, M. G., Bozeat, S., Ackerman, P., Atri, A., Barnum, C. J., Brundin, P., de Carvalho, C. M. A., Fleisher, A., Graf, A., Head, E., et al. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70287
Bawadi, H. A., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70338
Shah, D., Ramamohan, M. V., Mehta, K., Shejole, V., Murthy, S. S., Gupta, S., Samaria, A., Sosale, B., Dube, Y. P., Basu, U., et al. (2026) · Journal of Clinical Endocrinology and Metabolism · doi:10.52338/jocem.2026.6017
Cisneros, J. Z., Camilleri, M., & Grover, M. (2026) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/agl.v56i3.690
Chagas, G. C. L., Monteiro, M. R. L. M., EIRA, M. L., Chiappa, G. R., da Silva, J. C., & Abreu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71397
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
“In the OASIS 1 trial, oral semaglutide 50 mg achieved a 15.1% body mass reduction in non-diabetic adults [113], while the PIONEER 1 trial demonstrated significant HbA1c reduction and weight loss in T2DM patients, supporting its dual role in glycemic and weight control [114].”
InfluentialAlhazmi, A., & le Roux, C. W. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s637685
Сергеевич, А. А., Александровна, Б. Л., Яковлевна, З. К., Евгеньевич, Ш. И., Геннадьевна, Б. Т., Анатольевна, З. Л., Сергеевна, Щ. В., Владимирович, К. Д., Koryanova, K. N., Сергеевна, М. Е., et al. (2026) · Pharmacy & Pharmacology
Boye, K. S., Cutts, K. N., Zhao, Y., Steere, E., & Gelhorn, H. L. (2026) · Patient · doi:10.1007/s40271-026-00847-w
Yang, R., Zhang, S., Fu, Z., Yang, Y., Wang, Q., Zhou, Y., Li, J., Yang, R., Ning, S., Shi, Y., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70117
Yuan, B., Sui, Y., Li, H., Huang, J., Oh, Y. C., Zhao, Y., Li, X., Sun, Y., Liu, D., Basit, A. W., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115455
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Sahu, L., Nayak, L., Tripathy, A., Ramachandiran, S., Gunasekaran, B., & Lokaiah, T. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261499499
Zakeri, N., & Tolvanen, L. (2026) · Nutrients · doi:10.3390/nu18213524
Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
Bovee, L. B., & Thirumalai, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00469-y
Durve, S. A., Kuppili, S., & Lella, V. V. (2026) · GLOBAL JOURNAL OF MEDICAL STUDENTS · doi:10.25259/gjms_9_2026
N., S. N. L., Mano, V., Sugumar, D., & Devi, C. S. S. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i6.59887
GLP-1 based therapy of obesity and type 2 diabetes
Holst, J. J. (2026) · Diabetology International · doi:10.1007/s13340-026-00946-x
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.